文献速递临床试验与 GCP真实世界研究与卫生经济

电子症状监测对转移性癌症患者报告结局的影响:一项随机临床试验

Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01

PRO-TECT(Alliance AFT-39)集群随机试验纳入52家美国社区肿瘤机构的1191例转移性癌症成人患者,比较每周电子患者报告结局(PRO)症状监测与常规护理。3个月时PRO组躯体功能、症状控制和健康相关生活质量(HRQOL)均较常规护理组有统计学显著改善,平均改善约2.5分(0-100分量表)。主要结局总生存期结果尚未获得,结论应视为暂时性。

要点

  • 每周电子PRO症状监测较常规护理改善转移性癌症患者3个月躯体功能(平均差2.47分)。
  • PRO组症状控制与HRQOL亦优于常规护理(平均差分别为2.56分和2.43分)。
  • PRO组达到临床意义改善的比值比(OR)为1.35-1.50,主要结局总生存期结果尚未获得。

核心结论

  • 在转移性癌症成人患者中,每周电子PRO症状监测较常规护理在3个月时躯体功能、症状控制和HRQOL均有统计学显著改善,平均改善约2.5分(0-100分量表)。
  • 这些发现应视为暂时性,需等待主要结局总生存期的结果。

研究设计与样本

  • PRO-TECT(Alliance AFT-39)集群随机试验的次要结局报告,52家美国社区肿瘤机构随机分为电子PRO症状监测组或常规护理组。
  • 2017年10月至2020年3月纳入1191例接受治疗的转移性癌症成人,末次随访为2021年5月17日。
  • PRO组593例被要求通过互联网或自动电话系统每周完成调查,最长1年;严重或恶化症状触发照护团队警示;对照组598例接受常规护理。

主要发现

  • 3个月随访完成1066例(89.5%);患者平均年龄62.2岁,女性694例(58.3%)。
  • 躯体功能QLQ-C30评分:PRO组从74.27分升至75.81分,对照组从73.54分降至72.61分,平均差2.47(95%CI 0.41-4.53;P=0.02)。
  • 症状控制评分:PRO组从77.67分升至80.03分,对照组从76.75分降至76.55分,平均差2.56(95%CI 0.95-4.17;P=0.002)。
  • HRQOL评分:PRO组从78.11分升至80.03分,对照组从77.00分降至76.50分,平均差2.43(95%CI 0.90-3.96;P=0.002)。
  • PRO组较常规护理获得临床意义获益的比值比:躯体功能OR 1.35(95%CI 1.08-1.70;P=0.009),症状控制OR 1.50(95%CI 1.15-1.95;P=0.003),HRQOL OR 1.41(95%CI 1.10-1.81;P=0.006)。

局限性

  • 本报告为次要结局,主要结局总生存期结果尚未获得,结论应视为暂时性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Electronic systems that facilitate patient-reported outcome (PRO) surveys for patients with cancer may detect symptoms early and prompt clinicians to intervene. OBJECTIVE: To evaluate whether electronic symptom monitoring during cancer treatment confers benefits on quality-of-life outcomes. DESIGN, SETTING, AND PARTICIPANTS: Report of secondary outcomes from the PRO-TECT (Alliance AFT-39) cluster randomized trial in 52 US community oncology practices randomized to electronic symptom monitoring with PRO surveys or usual care. Between October 2017 and March 2020, 1191 adults being treated for metastatic cancer were enrolled, with last follow-up on May 17, 2021. INTERVENTIONS: In the PRO group, participants (n = 593) were asked to complete weekly surveys via an internet-based or automated telephone system for up to 1 year. Severe or worsening symptoms triggered care team alerts. The control group (n = 598) received usual care. MAIN OUTCOMES AND MEASURES: The 3 prespecified secondary outcomes were physical function, symptom control, and health-related quality of life (HRQOL) at 3 months, measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30; range, 0-100 points; minimum clinically important difference [MCID], 2-7 for physical function; no MCID defined for symptom control or HRQOL). Results on the primary outcome, overall survival, are not yet available. RESULTS: Among 52 practices, 1191 patients were included (mean age, 62.2 years; 694 [58.3%] women); 1066 (89.5%) completed 3-month follow-up. Compared with usual care, mean changes on the QLQ-C30 from baseline to 3 months were significantly improved in the PRO group for physical function (PRO, from 74.27 to 75.81 points; control, from 73.54 to 72.61 points; mean difference, 2.47 [95% CI, 0.41-4.53]; P = .02), symptom control (PRO, from 77.67 to 80.03 points; control, from 76.75 to 76.55 points; mean difference, 2.56 [95% CI, 0.95-4.17]; P = .002), and HRQOL (PRO, from 78.11 to 80.03 points; control, from 77.00 to 76.50 points; mean difference, 2.43 [95% CI, 0.90-3.96]; P = .002). Patients in the PRO group had significantly greater odds of experiencing clinically meaningful benefits vs usual care for physical function (7.7% more with improvements of ≥5 points and 6.1% fewer with worsening of ≥5 points; odds ratio [OR], 1.35 [95% CI, 1.08-1.70]; P = .009), symptom control (8.6% and 7.5%, respectively; OR, 1.50 [95% CI, 1.15-1.95]; P = .003), and HRQOL (8.5% and 4.9%, respectively; OR, 1.41 [95% CI, 1.10-1.81]; P = .006). CONCLUSIONS AND RELEVANCE: In this report of secondary outcomes from a randomized clinical trial of adults receiving cancer treatment, use of weekly electronic PRO surveys to monitor symptoms, compared with usual care, resulted in statistically significant improvements in physical function, symptom control, and HRQOL at 3 months, with mean improvements of approximately 2.5 points on a 0- to 100-point scale. These findings should be interpreted provisionally pending results of the primary outcome of overall survival. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03249090.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Basch E, Schrag D, Henson S, et al. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial. JAMA. 2022. PMID: 35661856. doi:10.1001/jama.2022.9265

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。